Amarin Corporation's triglyceride-lowering drug Vascepa will not be approved for use in a broader patient population until results from an additional study have been analyzed, according to an advisory panel to the U.S. FDA. The panel voted 9-2 against approval of the drug for patients who also take a cholesterol-lowering statin such as Pfizer Inc.'s Lipitor and are at high risk of coronary heart disease. Read the full story